Clinical Trials Logo
  1. Home
  2. Acute Heart Failure
  3. NCT04329234
  4. Details
NCT04329234 Clinical Trial

Korean Heart Failure Registry III

Acute Heart Failure Clinical Trial

— KorHF-III  

Official title:
Korean Heart Failure Registry Ⅲ of Korean Society of Heart Failure

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04329234
Other study ID # KorHF-III
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 1, 2018
Est. completion date December 31, 2027

Study information
Verified date March 2020
Source Seoul National University Bundang Hospital
Contact Dong-Ju Choi, MD, PhD
Phone 82317877007
Email djchoi@snubh.org
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

KorHF III is a multi-center, nationwide, prospective registry of the Korean Society of Heart Failure, which enrolls patients with acute heart failure in Korea.

The aim of this registry is to analyze the etiology, treatment, treatment, and prognosis to develop strategies for managing acute heart failure.

Recruitment information / eligibility
Status Recruiting
Enrollment 10000
Est. completion date December 31, 2027
Est. primary completion date December 31, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility All consecutive hospitalized adult heart failure patients who fulfill one of 1-3 and 4

Inclusion Criteria:

1. Symptoms of heart failure

2. Signs of heart failure

3. Lung congestion in Chest-x-ray

4. Objective finding of structural and/or functional disorder of the heart or elevated natriuretic peptide levels

Exclusion Criteria:

1. Patients younger than 18 years old

2. Patients who do no consent

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Korea, Republic of Seoul National University Bundang Hospital Seongnam

Sponsors (2)
Lead Sponsor Collaborator
Seoul National University Bundang Hospital Korean Society of Heart Failure

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary In-hospital mortality In-hospital mortality 5 years
Primary Post-discharge mortality Post-discharge mortality 5 years
Primary Post-discharge re-hospitalization Post-discharge re-hospitalization 5 years
See also
  Status Clinical Trial Phase
Terminated NCT02151383 - Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure Phase 2
Completed NCT02135835 - A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure Phase 4
Recruiting NCT05556044 - Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction Phase 3
Recruiting NCT04363697 - Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68) Phase 4
Completed NCT02122640 - Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department N/A
Completed NCT01193998 - Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department N/A
Not yet recruiting NCT01211886 - Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU) N/A
Not yet recruiting NCT06465498 - Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography N/A
Recruiting NCT05276219 - Optimized Treatment of Pulmonary Edema or Congestion Phase 4
Recruiting NCT05392764 - Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure Phase 3
Recruiting NCT03157219 - Manipal Heart Failure Registry (MHFR) N/A
Completed NCT06024889 - Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure. Phase 1/Phase 2
Terminated NCT04174794 - Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
Recruiting NCT05972746 - Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure N/A
Enrolling by invitation NCT02258984 - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial N/A
Completed NCT02141607 - Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
Completed NCT01870778 - Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF Phase 3
Recruiting NCT05986773 - Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance Phase 4
Recruiting NCT04163588 - Sequential Nephron Blockade in Acute Heart Failure Phase 3
Recruiting NCT03720288 - Acetazolamide in Patients With Acute Heart Failure Phase 3